Selling, General, and Administrative Costs: Geron Corporation vs Evotec SE

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of the biotechnology and pharmaceutical sectors, understanding financial health is crucial. Selling, General, and Administrative (SG&A) expenses are a key indicator of a company's operational efficiency. This analysis compares the SG&A expenses of Geron Corporation and Evotec SE from 2014 to 2023.

Evotec SE: A Steady Climb

Evotec SE has shown a remarkable increase in SG&A expenses, growing by over 840% from 2014 to 2023. This upward trend reflects the company's expansion and investment in administrative capabilities, peaking at approximately €170 million in 2023.

Geron Corporation: A Gradual Rise

Geron Corporation, while more conservative, has also seen a significant rise in SG&A expenses, increasing by around 310% over the same period. This growth, culminating in nearly €69 million in 2023, indicates strategic scaling efforts.

Both companies demonstrate distinct financial strategies, offering insights into their operational priorities and market positioning.